Loading...

We've got a brand new version of Simply Wall St! Try it out

Coloplast

SWX:COLOB
Snowflake Description

Excellent balance sheet established dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
COLOB
SWX
DKK168B
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Coloplast A/S develops and markets intimate healthcare products and services worldwide. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
COLOB Share Price and Events
7 Day Returns
0%
SWX:COLOB
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
11.2%
SWX:COLOB
33.3%
CH Medical Equipment
12.3%
CH Market
COLOB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Coloplast (COLOB) 0% 0% 0% 11.2% 76.6% 34%
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • COLOB underperformed the Medical Equipment industry which returned 33.3% over the past year.
  • COLOB underperformed the Market in Switzerland which returned 12.3% over the past year.
Price Volatility
COLOB
Industry
5yr Volatility vs Market

COLOB Value

 Is Coloplast undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Coloplast to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Coloplast.

SWX:COLOB Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:COLOB
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.84
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.84 (1 + (1- 22%) (0.72%))
0.896
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.896 * 5.96%)
8.61%

Discounted Cash Flow Calculation for SWX:COLOB using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Coloplast is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:COLOB DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (DKK, Millions) Source Present Value
Discounted (@ 8.61%)
2020 4,353.90 Analyst x10 4,008.58
2021 4,805.22 Analyst x9 4,073.22
2022 5,230.11 Analyst x9 4,081.76
2023 6,016.50 Analyst x2 4,323.07
2024 7,272.00 Analyst x1 4,810.77
2025 8,058.13 Est @ 10.81% 4,908.03
2026 8,747.09 Est @ 8.55% 4,905.11
2027 9,356.53 Est @ 6.97% 4,830.72
2028 9,904.79 Est @ 5.86% 4,708.20
2029 10,408.37 Est @ 5.08% 4,555.17
Present value of next 10 years cash flows DKK45,204.00
SWX:COLOB DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= DKK10,408.37 × (1 + 3.28%) ÷ (8.61% – 3.28%)
DKK201,315.48
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= DKK201,315.48 ÷ (1 + 8.61%)10
DKK88,104.69
SWX:COLOB Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= DKK45,204.00 + DKK88,104.69
DKK133,308.69
Equity Value per Share
(DKK)
= Total value / Shares Outstanding
= DKK133,308.69 / 212.42
DKK627.56
SWX:COLOB Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SWX:COLOB represents 0.13849x of CPSE:COLO B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.13849x
Value per Share
(Listing Adjusted, CHF)
= Value per Share (DKK) x Listing Adjustment Factor
= DKK 627.56 x 0.13849
CHF86.91
Value per share (CHF) From above. CHF86.91
Current discount Discount to share price of CHF109.85
= -1 x (CHF109.85 - CHF86.91) / CHF86.91
-26.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Coloplast is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Coloplast's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Coloplast's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:COLOB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in DKK DKK18.24
CPSE:COLO B Share Price ** CPSE (2019-11-14) in DKK DKK793.2
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Coloplast.

SWX:COLOB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:COLO B Share Price ÷ EPS (both in DKK)

= 793.2 ÷ 18.24

43.48x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Coloplast is overvalued based on earnings compared to the CH Medical Equipment industry average.
  • Coloplast is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Coloplast's expected growth come at a high price?
Raw Data
SWX:COLOB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 43.48x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
10.2%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

SWX:COLOB PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 43.48x ÷ 10.2%

4.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Coloplast is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Coloplast's assets?
Raw Data
SWX:COLOB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in DKK DKK32.54
CPSE:COLO B Share Price * CPSE (2019-11-14) in DKK DKK793.2
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:COLOB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:COLO B Share Price ÷ Book Value per Share (both in DKK)

= 793.2 ÷ 32.54

24.37x

* Primary Listing of Coloplast.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Coloplast is overvalued based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Coloplast's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Coloplast has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

COLOB Future Performance

 How is Coloplast expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Coloplast expected to grow at an attractive rate?
  • Coloplast's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Coloplast's earnings growth is expected to exceed the Switzerland market average.
  • Coloplast's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:COLOB Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:COLOB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 10.2%
SWX:COLOB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 7.5%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:COLOB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:COLOB Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 26,277 8,178 6,687 6
2023-09-30 24,339 6,976 6,135 6
2022-09-30 22,516 6,143 5,509 11
2021-09-30 20,849 5,659 5,098 15
2020-09-30 19,352 5,187 4,614 17
2019-11-14
SWX:COLOB Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2019-09-30 17,939 4,357 3,873
2019-06-30 17,555 4,161 4,119
2019-03-31 17,181 4,177 3,999
2018-12-31 16,815 4,126 3,896
2018-09-30 16,449 4,361 3,845
2018-06-30 16,195 4,370 3,816
2018-03-31 15,882 4,111 3,778
2017-12-31 15,728 4,004 3,791
2017-09-30 15,528 3,251 3,797
2017-06-30 15,287 2,994 3,211
2017-03-31 15,061 2,492 3,279
2016-12-31 14,780 2,653 3,264

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Coloplast's earnings are expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).
  • Coloplast's revenue is expected to grow by 7.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:COLOB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Coloplast Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:COLOB Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30 32.21 35.23 30.10 3.00
2023-09-30 29.32 31.51 27.90 3.00
2022-09-30 26.19 28.15 23.35 10.00
2021-09-30 24.04 25.45 22.42 11.00
2020-09-30 21.78 22.90 21.04 14.00
2019-11-14
SWX:COLOB Past Financials Data
Date (Data in DKK Millions) EPS *
2019-09-30 18.24
2019-06-30 19.40
2019-03-31 18.84
2018-12-31 18.36
2018-09-30 18.12
2018-06-30 17.98
2018-03-31 17.80
2017-12-31 17.86
2017-09-30 17.89
2017-06-30 15.16
2017-03-31 15.48
2016-12-31 15.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Coloplast is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Coloplast's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Coloplast has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

COLOB Past Performance

  How has Coloplast performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Coloplast's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Coloplast's year on year earnings growth rate has been positive over the past 5 years.
  • Coloplast's 1-year earnings growth is less than its 5-year average (0.7% vs 16.1%)
  • Coloplast's earnings growth has exceeded the CH Medical Equipment industry average in the past year (0.7% vs -9.5%).
Earnings and Revenue History
Coloplast's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Coloplast Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:COLOB Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 17,939.00 3,873.00 5,970.00 692.00
2019-06-30 17,555.00 4,119.00 5,750.00 686.00
2019-03-31 17,181.00 3,999.00 5,620.00 671.00
2018-12-31 16,815.00 3,896.00 5,485.00 663.00
2018-09-30 16,449.00 3,845.00 5,375.00 640.00
2018-06-30 16,195.00 3,816.00 5,315.00 619.00
2018-03-31 15,882.00 3,778.00 5,211.00 605.00
2017-12-31 15,728.00 3,791.00 5,104.00 594.00
2017-09-30 15,528.00 3,797.00 4,994.00 574.00
2017-06-30 15,287.00 3,211.00 4,880.00 565.00
2017-03-31 15,061.00 3,279.00 4,785.00 551.00
2016-12-31 14,780.00 3,264.00 4,731.00 521.00
2016-09-30 14,681.00 3,143.00 4,693.00 509.00
2016-06-30 14,563.00 1,297.00 4,690.00 494.00
2016-03-31 14,417.00 1,028.00 4,627.00 477.00
2015-12-31 14,264.00 927.00 4,583.00 458.00
2015-09-30 13,909.00 899.00 4,488.00 442.00
2015-06-30 13,502.00 3,162.00 4,343.00 437.00
2015-03-31 13,096.00 3,241.00 4,220.00 418.00
2014-12-31 12,666.00 2,407.00 4,088.00 406.00
2014-09-30 12,428.00 2,390.00 4,002.00 390.00
2014-06-30 12,184.00 2,298.00 3,959.00 375.00
2014-03-31 12,008.00 2,220.00 3,944.00 370.00
2013-12-31 11,833.00 2,874.00 3,889.00 382.00
2013-09-30 11,635.00 2,711.00 3,854.00 380.00
2013-06-30 11,514.00 2,570.00 3,937.00 371.00
2013-03-31 11,384.00 2,448.00 3,901.00 360.00
2012-12-31 11,234.00 2,327.00 3,915.00 339.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Coloplast made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Coloplast used its assets more efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Coloplast's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Coloplast's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Coloplast has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

COLOB Health

 How is Coloplast's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Coloplast's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Coloplast is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Coloplast's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Coloplast's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Coloplast Company Filings, last reported 1 month ago.

SWX:COLOB Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 6,913.00 1,066.00 669.00
2019-06-30 5,939.00 2,840.00 755.00
2019-03-31 6,173.00 2,584.00 620.00
2018-12-31 5,192.00 3,039.00 737.00
2018-09-30 6,418.00 1,262.00 607.00
2018-06-30 5,202.00 2,975.00 761.00
2018-03-31 5,376.00 3,183.00 919.00
2017-12-31 4,711.00 2,895.00 821.00
2017-09-30 5,952.00 1,358.00 629.00
2017-06-30 4,958.00 2,547.00 627.00
2017-03-31 5,064.00 2,662.00 776.00
2016-12-31 4,214.00 2,880.00 924.00
2016-09-30 5,068.00 222.00 1,035.00
2016-06-30 4,499.00 923.00 624.00
2016-03-31 4,923.00 25.00 602.00
2015-12-31 4,026.00 391.00 613.00
2015-09-30 4,706.00 100.00 1,400.00
2015-06-30 5,793.00 779.00 854.00
2015-03-31 6,473.00 467.00 872.00
2014-12-31 5,395.00 367.00 628.00
2014-09-30 6,283.00 99.00 1,590.00
2014-06-30 5,423.00 154.00 805.00
2014-03-31 5,847.00 130.00 1,086.00
2013-12-31 6,090.00 129.00 937.00
2013-09-30 6,769.00 126.00 1,871.00
2013-06-30 6,155.00 146.00 952.00
2013-03-31 6,350.00 1,311.00 2,566.00
2012-12-31 5,921.00 1,335.00 2,325.00
  • Coloplast's level of debt (15.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.6% vs 15.4% today).
  • Debt is well covered by operating cash flow (408.7%, greater than 20% of total debt).
  • Coloplast earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Coloplast's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Coloplast has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

COLOB Dividends

 What is Coloplast's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.14%
Current annual income from Coloplast dividends. Estimated to be 2.62% next year.
If you bought CHF2,000 of Coloplast shares you are expected to receive CHF43 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Coloplast's pays a higher dividend yield than the bottom 25% of dividend payers in Switzerland (1.85%).
  • Coloplast's dividend is below the markets top 25% of dividend payers in Switzerland (3.63%).
Upcoming dividend payment

Purchase Coloplast before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:COLOB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:COLOB Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2024-09-30 31.71 1.00
2023-09-30 28.36 1.00
2022-09-30 22.11 12.00
2021-09-30 20.54 16.00
2020-09-30 18.79 16.00
2019-11-14
SWX:COLOB Past Annualized Dividends Data
Date (Data in DKK) Dividend per share (annual) Avg. Yield (%)
2019-11-05 17.000 2.155
2019-08-14 16.000 1.983
2019-05-02 16.000 2.107
2018-11-01 16.000 2.481
2018-08-08 15.500 2.376
2017-11-02 15.000 2.744
2017-08-16 13.500 2.577
2017-05-03 13.500 2.441
2016-11-02 13.500 2.746
2016-08-16 12.500 2.506
2016-05-03 12.500 2.488
2015-11-03 12.500 2.389
2015-08-11 12.000 2.555
2015-05-05 12.000 2.498
2014-12-04 11.500 2.181
2014-08-13 11.000 2.255
2014-05-07 11.000 2.288
2013-11-01 7.000 1.770
2013-10-31 7.000 1.981
2012-12-11 4.000 1.292
2011-11-01 2.800 1.384
2010-11-03 2.000 1.298
2009-11-06 1.400 1.199
2008-11-20 1.200 1.589

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of Coloplast's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.5x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.2x coverage).
X
Income/ dividend checks
We assess Coloplast's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Coloplast afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Coloplast has a total score of 5/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

COLOB Management

 What is the CEO of Coloplast's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kristian Villumsen
COMPENSATION DKK17,500,000
AGE 49
TENURE AS CEO 0.9 years
CEO Bio

Mr. Kristian Villumsen has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an Executive Vice President of Chronic Care at Coloplast A/S since July 2014 until December 4, 2018. Mr. Villumsen has responsibility for Global Marketing, R&D and sales regions within Ostomy - and Continence care. Since joining Coloplast in 2008, he has been Head of Global Marketing, Europe 11 and Region Emerging Markets. He has extensive knowledge of the medico and life science industry as well as solid international and managerial experience in both European and emerging markets. He has been an Independent Director at Chr. Hansen Holding A/S since November 2014. He is a Board member in six subsidiaries wholly owned by Coloplast A/S. Mr. Villumsen holds a Master of Arts in Political Science from Aarhus University, Denmark and a Master’s in Public Policy from Harvard University, USA.

CEO Compensation
  • Kristian's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.
  • Kristian's remuneration is lower than average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Coloplast management team in years:

5.3
Average Tenure
49
Average Age
  • The average tenure for the Coloplast management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Kristian Villumsen

TITLE
President & CEO
COMPENSATION
DKK18M
AGE
49
TENURE
0.9 yrs

Anders Lonning-Skovgaard

TITLE
Executive VP & CFO
COMPENSATION
DKK10M
AGE
47
TENURE
5.3 yrs

Allan Rasmussen

TITLE
Executive Vice President of Global Operations
COMPENSATION
DKK10M
AGE
52
TENURE
5.3 yrs

Paul Marcun

TITLE
Executive Vice President of Chronic Care
COMPENSATION
DKK9M
AGE
53
TENURE
0.8 yrs

Thomas Barfod

TITLE
Senior Controller & Director
COMPENSATION
DKK450K
AGE
49

Ellen Bjurgert

TITLE
Vice President of Investor Relations
TENURE
3.1 yrs

Dennis Kaysen

TITLE
Director of Corporate Communications

Nicolai Andersen

TITLE
Senior Vice President of Wound Care

Alain Morvan

TITLE
Senior Vice President of Sales Europe
TENURE
7.6 yrs

Oliver Johansen

TITLE
Senior Vice President of Global R&D
AGE
48
TENURE
6.9 yrs
Board of Directors Tenure

Average tenure and age of the Coloplast board of directors in years:

2.9
Average Tenure
56
Average Age
  • The average tenure for the Coloplast board of directors is less than 3 years, this suggests a new board.
Board of Directors

Lars Rasmussen

TITLE
Chairman of the Board
COMPENSATION
DKK21M
AGE
60
TENURE
0.9 yrs

Niels Louis-Hansen

TITLE
Deputy Chairman
COMPENSATION
DKK910K
AGE
72

Thomas Barfod

TITLE
Senior Controller & Director
COMPENSATION
DKK450K
AGE
49
TENURE
12.9 yrs

Jørgen Tang-Jensen

TITLE
Independent Director
COMPENSATION
DKK767K
AGE
63
TENURE
11.9 yrs

Birgitte Nielsen

TITLE
Independent Director
COMPENSATION
DKK634K
AGE
56
TENURE
3.9 yrs

Jette Nygaard-Andersen

TITLE
Independent Director
COMPENSATION
DKK532K
AGE
51
TENURE
3.9 yrs

Carsten Hellmann

TITLE
Independent Director
COMPENSATION
DKK634K
AGE
55
TENURE
1.9 yrs

Nikolaj Gundersen

TITLE
Director
COMPENSATION
DKK369K
AGE
50
TENURE
1.8 yrs

Roland Pedersen

TITLE
Director
COMPENSATION
DKK369K
AGE
57
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
X
Management checks
We assess Coloplast's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Coloplast has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

COLOB News

Simply Wall St News

COLOB Company Info

Description

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit to individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catherisation for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies; and directly to users. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Details
Name: Coloplast A/S
COLOB
Exchange: SWX
Founded: 1954
DKK24,493,457,657
212,423,000
Website: http://www.coloplast.com
Address: Coloplast A/S
Holtedam 1-3,
Humlebæk,
3050,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE COLO B Class B Shares OMX Nordic Exchange Copenhagen DK DKK 25. Mar 1993
OTCPK CLPB.F Class B Shares Pink Sheets LLC US USD 25. Mar 1993
DB CBHD Class B Shares Deutsche Boerse AG DE EUR 25. Mar 1993
LSE 0QBO Class B Shares London Stock Exchange GB DKK 25. Mar 1993
SWX COLOB Class B Shares SIX Swiss Exchange CH CHF 25. Mar 1993
WBAG COLO Class B Shares Wiener Boerse AG AT EUR 25. Mar 1993
BMV 0QBO N Class B Shares Bolsa Mexicana de Valores MX MXN 25. Mar 1993
BATS-CHIXE COLOBC Class B Shares BATS 'Chi-X Europe' GB DKK 25. Mar 1993
OTCPK CLPB.Y UNSPONSORD ADR Pink Sheets LLC US USD 23. Nov 2010
Number of employees
Current staff
Staff numbers
12,074
Coloplast employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 21:33
End of day share price update: 2019/11/14 00:00
Last estimates confirmation: 2019/11/14
Last earnings filing: 2019/11/05
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.